Investor FAQs
Radius common stock is traded on the NASDAQ Global Market under the ticker symbol "RDUS."
750469 207
22 Boston Wharf Road
7th Floor
Boston, MA 02210
Radius does not offer a direct stock purchase plan. Shares of the Company should be purchased through a broker.
Radius does not currently pay a dividend.
Computershare
Investor Center Website
Shareholder Online Inquiries
Email
Telephone inquiries
1-877-373-6374 (US, Canada, Puerto Rico)
1-781-575-3100 (non-US)
Written requests
Computershare
P.O. Box 505000
Louisville, KY 40233-5000
By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202
To replace lost certificates, contact the transfer agent at:
Computershare
Investor Center Website
Shareholder Online Inquiries
Email
Telephone inquiries
1-877-373-6374 (US, Canada, Puerto Rico)
1-781-575-3100 (non-US)
Written requests
Computershare
P.O. Box 505000
Louisville, KY 40233-5000
By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202
To notify of a change in address, contact the transfer agent at:
Computershare
Investor Center Website
Shareholder Online Inquiries
Email
Telephone inquiries
1-877-373-6374 (US, Canada, Puerto Rico)
1-781-575-3100 (non-US)
Written requests
Computershare
P.O. Box 505000
Louisville, KY 40233-5000
By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202
Radius’ fiscal year is based on the calendar year.
First Quarter ends 3/31, Second Quarter ends 6/30, Third Quarter ends 9/30 and Fourth Quarter ends 12/31.
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.